Evogene releases Q3 results with large improvements over last year’s numbers

November 23, 2012 |

In Israel, Evogene has announced its Q3 results, with revenues increasing to $4M, an 18% improvement over Q3 of 2011 due in part to last year’s collaboration with Monsanto. Evogene’s president and CEO, Ofer Haviv, indicated that the company will focus on four divisions in the coming year: yield and abiotic stress, biotic stress, ag-chemicals, and biofuel. R&D spending increased from $4.6M in 2011 to $5.2M, and Evogene attributes the higher expenses to research for the expansion of the biofuel program.

Print Friendly

Tags: , ,

Category: International

Comments are closed.